A retrospective, multicenter, real world study of Olaparib combined with abiraterone versus olaparib alone for patients with DNA-repair deficient metastatic castration-resistant prostate cancer
Latest Information Update: 19 Jul 2022
At a glance
- Drugs Olaparib (Primary) ; Abiraterone
- Indications Prostate cancer
- Focus Therapeutic Use
Most Recent Events
- 19 Jul 2022 New trial record
- 07 Jun 2022 According to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology,Primary endpoint (Overall survival) has been met.
- 07 Jun 2022 According to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology,Primary endpoint (Progression-free survival (PFS) has been met.